Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when STOK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStoke Therapeutics expands board to 10 directors, appoints G. Clare Kahn as R&D chair
Filed April 7, 2026 · Period ending April 3, 2026 · ~1 min read
Key Changes
-
medium
Board expanded from 9 to 10 seats and appointed G. Clare Kahn, Ph.D. as Class I director effective April 3, 2026. Dr. Kahn will chair the Research & Development Committee and serve on the Nominating Committee.
Item 5.02 verify on EDGAR → -
low
Dr. Kahn received standard director compensation: $45,000 annual cash retainer plus initial stock option grant for 30,782 shares valued at ~$724,000, vesting quarterly over three years.
Item 5.02 verify on EDGAR → -
low
Board confirmed Dr. Kahn meets independence requirements under Securities Act of 1933 and Nasdaq listing standards, with no related party transactions.
Item 5.02 verify on EDGAR →
Summary
Stoke Therapeutics expanded its board of directors from nine to ten members and appointed G. Clare Kahn, Ph.D. as a new Class I director effective April 3, 2026. Dr. Kahn will serve until the 2026 Annual Meeting and was immediately named chairperson of the Research and Development Committee, a role that signals the company's focus on its clinical pipeline.
She also joined the Nominating and Corporate Governance Committee. For retail investors, board appointments at clinical-stage biotech companies like Stoke often reflect strategic priorities. Placing Dr. Kahn in the R&D chair role suggests the company values her expertise as it advances its therapeutic programs.
The compensation package—$45,000 annual retainer plus stock options worth approximately $724,000—is standard for non-employee directors at companies of this size. Watch for the company's 2026 proxy statement, which will provide Dr. Kahn's full biography and qualifications. Her background and experience may offer clues about Stoke's near-term clinical development strategy and therapeutic focus areas.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 3, 2026, the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (“Stoke” or the “Company”), increased the size of the Board to ten (10) directors and, following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed G. Clare Kahn, Ph.D. to serve on the Board as a Class I director, effective immediately, to fill the vacancy created by the increase in Board size.
The Board expanded from nine to ten directors and appointed Dr. G. Clare Kahn as a new Class I director. Dr. Kahn will serve until the 2026 Annual Meeting and was also appointed to the Nominating and Corporate Governance Committee and as chairperson of the Research and Development Committee.
Event · Item 7.01 — Regulation FD Disclosure
Company announced Dr. Kahn's appointment via press release furnished under Regulation FD.
Added in current filing · verify on EDGAR →
On April 7, 2026, the Company issued a press release regarding Dr. Kahn’s appointment, which is included as Exhibit 99.1 to this Form 8-K.
The company disclosed the appointment of Dr. Kahn through a press release. The 8-K provides no details about Dr. Kahn's role, title, or responsibilities; those details are contained in the referenced press release exhibit. This is a Regulation FD disclosure, meaning the information is being publicly furnished to ensure fair disclosure to all investors simultaneously.
Event · Item 9.01 — Financial Statements and Exhibits
Stoke Therapeutics filed an 8-K attaching a press release dated April 7, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press release issued by Stoke Therapeutics, Inc. dated April 7, 2026
The 8-K references an attached press release dated April 7, 2026. The filing body itself contains no substantive disclosure about the press release content, making this a procedural filing to satisfy disclosure requirements for whatever event the press release announces.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify